The Dual Antiplatelet Therapy Trial after the FDA Update: Noncardiovascular Deaths, Cancer and Optimal Treatment Duration

Publisher： Karger

E-ISSN： 1421-9751|132|2|74-80

ISSN： 0008-6312

Source： Cardiology, Vol.132, Iss.2, 2015-06, pp. : 74-80

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Optimal Duration of Dual Antiplatelet Therapy after Drug‐Eluting Stents: Meta‐Analysis of Randomized Trials

By  

CARDIOVASCULAR THERAPEUTICS (ELECTRONIC), Vol. 33, Iss. 5, 2015-10 ,pp. : 253-263

John Wiley & Sons Inc

Access to resources Recommend Favorite

Meta-Analysis of Trials Comparing Oral Anticoagulation and Aspirin versus Dual Antiplatelet Therapy after Coronary Stenting

By  

Cardiology, Vol. 104, Iss. 2, 2005-08 ,pp. : 101-106

Karger

Access to resources Recommend Favorite

Response to Dual Antiplatelet Therapy Does Not Impact Bleeding Risks in Patients Undergoing Oral Surgery after Acute Coronary Syndromes

By  

Cardiology, Vol. 132, Iss. 2, 2015-07 ,pp. : 119-123

Karger

Access to resources Recommend Favorite

Gastrointestinal Adverse Events after Dual Antiplatelet Therapy: Clopidogrel Is Safer than Ticagrelor, but Prasugrel Data Are Lacking or Inconclusive

By  

Cardiology, Vol. 126, Iss. 1, 2013-07 ,pp. : 35-40

Karger

Access to resources Recommend Favorite

In reference to what is the optimal perioperative management of antiplatelet therapy?

By  

THE LARYNGOSCOPE, Vol. 126, Iss. 9, 2016-09 ,pp. : E317-E317

John Wiley & Sons Inc

Access to resources Recommend Favorite